First-in-human anti-Trop2 CAR-T cell therapy in refractory INI-1/BRM-deficient sinonasal carcinoma: A case report
Molecular Therapy Oncology · 2026-12 · 34 (4) · 201366
DOI: 10.1016/j.omton.2026.201366 ↗Kurz gefasst
Fallbericht in der Zeitschrift Molecular Therapy Oncology, 2026-12. Verfasst von Guangfei Li und 19 weiteren Autor:innen. Beteiligte Einrichtung: ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Hospital Development Center, Shanghai Clinical Research Center, National Natural Science Foundation of China.
Abstract (Originalsprache)
INI-1-deficient sinonasal carcinoma is an aggressive malignancy with a dismal prognosis and no established salvage therapies. While trophoblast cell-surface antigen 2 (Trop2) is a promising immunotherapeutic target, its clinical utility in sinonasal cancer remains unexplored. We report the first-in-human application of anti-Trop2 CAR-T cell therapy in a 61-year-old male with refractory INI-1/BRM-deficient sinonasal carcinoma. Following lymphodepletion, the CAR-T cells demonstrated robust in vivo expansion, peaking within 14 days and coinciding with transient cytokine elevation. Toxicities were manageable but included grade 2 cytokine release syndrome and grade 3 hepatotoxicity that required multiple sessions of plasma exchange. Notably, MRI at day 78 post-infusion revealed dramatic tumor regression with extensive necrosis and liquefaction, which correlated with the complete resolution of intractable orbital pain. This single-case observation provides preliminary proof-of-concept for the safety and anti-tumor activity of Trop2-targeted CAR-T cells in refractory sinonasal malignancies, though further studies are needed to confirm durability and generalizability.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China.
- School of Pharmacy, East China Normal University, Shanghai 200062, China.
- Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai 200000, China.
- Department of Nursing, Eye & ENT Hospital, Fudan University, Shanghai 200031, China.
- Department of Pharmacy, Eye & ENT Hospital, Fudan University, Shanghai 200031, China.
- Shanghai Key Laboratory of Gene Editing and Cell Therapy for Rare Diseases, Fudan University, Shanghai 200031, China.
Förderung
- Shanghai Hospital Development Center
- Shanghai Clinical Research Center
- National Natural Science Foundation of China
- Shanghai Institute of Materia Medica Rising-Star Program
Zitieren
APA
Li, G., Lai, Y., Wang, L., Zhu, H., Chen, M., Wang, J., Huang, T., Kang, L., Xu, N., Li, M., Lou, X., Yu, Z., Wang, W., Fan, M., Wu, J., Wu, H., Yu, L., He, P., Yu, H., & Chen, J. (2026). First-in-human anti-Trop2 CAR-T cell therapy in refractory INI-1/BRM-deficient sinonasal carcinoma: A case report. Molecular Therapy Oncology, 34(4), 201366. https://doi.org/10.1016/j.omton.2026.201366
Vancouver
Li G, Lai Y, Wang L, Zhu H, Chen M, Wang J, et al. First-in-human anti-Trop2 CAR-T cell therapy in refractory INI-1/BRM-deficient sinonasal carcinoma: A case report. Molecular Therapy Oncology. 2026;34(4):201366. doi:10.1016/j.omton.2026.201366
BibTeX
@article{Li2026,
author = {Li, Guangfei and Lai, Yuting and Wang, Liang and Zhu, Hongjia and Chen, Min and Wang, Jifang and Huang, Taomin and Kang, Liqing and Xu, Nan and Li, Minghao and Lou, Xiaoyan and Yu, Zhou and Wang, Wei and Fan, Minghao and Wu, Jiali and Wu, Haitao and Yu, Lei and He, Peijie and Yu, Hongmeng and Chen, Jian},
title = {First-in-human anti-Trop2 CAR-T cell therapy in refractory INI-1/BRM-deficient sinonasal carcinoma: A case report},
journal = {Molecular Therapy Oncology},
year = {2026},
volume = {34},
number = {4},
pages = {201366},
doi = {10.1016/j.omton.2026.201366}
}
EUVIMED